Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force.
about
Mouse models of neurofibromatosis 1 and 2.An Update on the Ophthalmologic Features in the PhakomatosesRASopathies: unraveling mechanisms with animal modelsThe molecular biology of WHO grade I astrocytomasNeurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytesRegion-specific astrogliosis in brains of mice heterozygous for mutations in the neurofibromatosis type 1 (Nf1) tumor suppressorHigh-Dose Intravenous Vitamin C Treatment of a Child with Neurofibromatosis Type 1 and Optic Pathway Glioma: A Case Report.Von recklinghausens disease: a series of four cases with variable expressionOrbitofacial neurofibromatosis: clinical characteristics and treatment outcomePediatric low-grade gliomas and the need for new options for therapy: Why and how?Intracranial gliomas in neurofibromatosis type 1.Pheochromocytoma associated with neurofibromatosis type 1: concepts and current trends.Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity.Pediatric low-grade gliomas: how modern biology reshapes the clinical field.Phakomatoses. Part I: Neurofibromatosis type 1: common and uncommon neuroimaging findings.Ultrastructural characterization of the optic pathway in a mouse model of neurofibromatosis-1 optic gliomaMoyamoya syndrome after radiation therapy for optic pathway glioma: case report.Neoplasms associated with germline and somatic NF1 gene mutationsSex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.Neurofibromatosis type 1: modeling CNS dysfunction.Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation.Neurofibromatosis type 1 and sporadic optic gliomas.An 80-year experience with optic nerve glioma cases at the Armed Forces Institute of Pathology: evolution from museum to molecular evaluation suggests possibe interventions in the cellular senescence and microglial pathways (an American OphthalmologRadiofrequency ablation and excision of multiple cutaneous lesions in neurofibromatosis type 1.Clinical features and pathobiology of neurofibromatosis 1.Neurofibromin in the brain.Neurofibromatosis 1: clinical review and exceptions to the rules.Intracranial neoplasms in children with neurofibromatosis 1.High spatial resolution imaging mass spectrometry of human optic nerve lipids and proteins.Neurofibromatosis-1 heterozygosity impairs CNS neuronal morphology in a cAMP/PKA/ROCK-dependent mannerThe impact of coexisting genetic mutations on murine optic glioma biology.3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.Primary tumours of the optic nerve and its sheath.Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology programIsolated lymphoma of the optic nerve, chiasm and tract: A case report.Spectrum and prevalence of vasculopathy in pediatric neurofibromatosis type 1.MRI Screening for Optic Gliomas in Neurofibromatosis Type 1Anterior visual pathway gliomas: The last 30 years.Impact of vision loss among survivors of childhood central nervous system astroglial tumors.Guidelines for the diagnosis and management of individuals with neurofibromatosis 1
P2860
Q24682869-6774F417-AC6E-4021-9229-6D7B87B25C2AQ26738915-22E6F7FD-1EAF-4B25-8BB5-519C097E4366Q26800379-E0FEBA3D-54DA-4CF8-B458-60D536F36D37Q27010414-7A5824E0-463A-4817-B66E-37EBFB5D8E69Q28506980-E0A90EC4-26DA-43F0-AA4C-1F3F259C3F31Q28591692-1E966C9C-93A8-4824-A4C7-30ED89A15024Q30370309-38863306-0615-47B9-955A-E8875B076FF7Q30389804-6037C05C-12B8-4480-B3FE-7A8E0E57E5F6Q30455828-547C97A4-B202-42BB-95AB-DA84C9E5713FQ33607387-67A52126-4A22-400B-B533-2F5633C3A834Q33723870-6DB1F613-109A-48EA-82A8-85BB073CE27FQ33763898-90CD6570-7161-4534-9A9F-93F992C4DAA7Q33831164-5F6A2F68-FC43-4A41-A2AA-2949D43CB64BQ33847771-A0F76E75-6DE3-4FCE-81D6-481FE6CFE2B9Q33986450-9A00320B-0612-4B66-AE5B-C37B49284403Q34079603-16762ED9-FBFB-4DFB-85D8-0AEDA6932D92Q34099875-E4EB9AC9-5816-47FD-8C0A-4239606ED279Q34125947-58D32FFE-A1A7-4B5D-B23C-A18B988BDE57Q34231047-A6385D04-ECEB-40C9-BAC7-0C63604C9C1CQ34305314-C9788F0B-258C-4675-8CF0-CA426AD0D709Q34441257-6B8C629A-2DE6-420C-B50C-497F0F812C1AQ34524695-9A0422A9-A8B1-4202-8BA0-92EA7A53E804Q34525316-135ABAAE-0BFE-463B-8D1E-CAC0294C3790Q34567352-C162B701-EE87-4398-9A70-79972EEA8AF2Q34982033-A7178297-EA19-4969-8F67-D6E357C75A75Q34982048-DAC32348-6130-43CF-8657-26525CFF18CDQ34982060-B4F97EE3-FFB2-4FF6-8CBB-4ABADF352346Q34982069-16BBFE81-C0A1-465A-8A72-92680EE16EE4Q35609660-DB262A08-8DA7-4D49-AD80-3ACD7E3CF937Q35613659-6333689B-CB24-4254-9CD4-A759C86E07C5Q35788566-351AE3B4-33E0-4962-9E2E-74127E9B4E3FQ35925481-846908F6-940F-4D2F-9F7A-EB9E3158CFF5Q35943989-734B6FE7-1669-49C3-AC8E-6044F913FB5CQ36013340-8BBCDBFB-072E-427B-B8D6-AB1429FD59C0Q36336253-CFB198AC-CDAA-4D9E-987B-482FCCAAD779Q36395077-F48FA7F6-2ED4-4FC5-86D8-51D2FBF257BFQ36561895-E7BE8ECA-90C6-46C8-8FF8-18C0A9729621Q36567082-867DE512-B9AE-4265-A73A-4DF90A8294F2Q36609635-DA2BEC3B-0913-4046-B3D4-BEFA0E0C42F6Q36653938-0B1564BA-F3AE-4BB6-88CC-F5B8EA386A37
P2860
Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Optic pathway gliomas in child ...... tic Pathway Glioma Task Force.
@en
Optic pathway gliomas in child ...... tic Pathway Glioma Task Force.
@nl
type
label
Optic pathway gliomas in child ...... tic Pathway Glioma Task Force.
@en
Optic pathway gliomas in child ...... tic Pathway Glioma Task Force.
@nl
prefLabel
Optic pathway gliomas in child ...... tic Pathway Glioma Task Force.
@en
Optic pathway gliomas in child ...... tic Pathway Glioma Task Force.
@nl
P2093
P2860
P356
P1433
P1476
Optic pathway gliomas in child ...... ptic Pathway Glioma Task Force
@en
P2093
P2860
P304
P356
10.1002/ANA.410410204
P577
1997-02-01T00:00:00Z